At close: 5:29 PM GMT+1
Key Executives
Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in SEK.
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Peter Selin | Chief Executive Officer | 2.62M | -- | 1973 |
| Dr. Thomas Olin Ph.D. | Executive VP & Director | 3.45M | -- | 1958 |
| Mr. Hans Richter | Chief Financial Officer | -- | -- | 1949 |
| Dr. Robert Edfors | Chief Medical Officer | -- | -- | -- |
Kancera AB (publ)
Karolinska Institutet Science Park
Nanna Svarts väg 4
Solna, 171 65
Sweden
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 5
Description
Kancera AB (publ) develops drugs for inflammatory diseases and cancer in Sweden and internationally. The company is developing small molecule drug candidates KAND567, which is in phase IIa clinical trial for inflammatory heart disease following infarction, as well as KAND145, which is in phase I study in healthy subjects to document desired dose levels against cancer; and Phase IIa study for the treatment of ovarian cancer. It also develops KAN571, a ROR1 inhibitor for the treatment of mantle cell lymphoma and B-cell malignancy. Kancera AB (publ) was incorporated in 2010 and is headquartered in Solna, Sweden.
Corporate Governance
Kancera AB (publ)’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.
Upcoming Events
November 15, 2024 at 10:59 AM UTC
Kancera AB (publ) Earnings Date
Recent Events
Recent Events Information Not Available
Related Tickers
DMYD-B.ST Diamyd Medical AB (publ)
12.34
-0.16%
COMBI.ST CombiGene AB (publ)
2.5600
-2.29%
ONCOZ.ST OncoZenge AB (publ)
9.90
-4.26%
FLUI.ST Fluicell AB (publ)
0.0530
-3.99%
ISOFOL.ST Isofol Medical AB (publ)
3.2750
+13.52%
ACTI.ST Active Biotech AB (publ)
0.3000
+33.63%
8WK.F Abera Bioscience AB
0.3130
+1.29%
ABERA.ST Abera Bioscience AB
3.8600
-0.26%
DBP-B.ST Double Bond Pharmaceutical Int.
0.4350
+1.64%
LPGO.ST Lipigon Pharmaceuticals AB (publ)
0.1372
+1.03%